-- 火曜日、米軍がホルムズ海峡封鎖を打破するための「フリーダム作戦」を開始したことを受け、原油価格は下落した。 ムルバン原油先物(期近)は1.2%下落し1バレル=106ドル、ブレント原油先物は2%下落し1バレル=112.06ドルとなった。 しかし、アナリストらによると、米軍とイラン軍の直接交戦と、アラブ首長国連邦(UAE)のフジャイラ石油ターミナルへのドローン攻撃により、下落幅は急激に縮小した。これらの出来事は1カ月にわたる停戦を破り、長期的な世界的エネルギー危機への懸念を再燃させた。 アナリストらは、米海軍艦艇への攻撃の速報を受け、原油市場は依然として警戒態勢にあると指摘した。 これらの戦闘は、米国がペルシャ湾に取り残された商船を救出するための作戦を開始した直後に勃発した。 米中央軍は、米商船2隻がホルムズ海峡を無事通過したことを確認したと報じられているが、その後米軍とイラン軍の間で直接的な銃撃戦が発生し、4週間前に成立した停戦協定の存続が危ぶまれている。 4月8日の停戦開始以来初めて、アラブ首長国連邦(UAE)がイランのミサイルとドローンを迎撃したと報告したことで、地域情勢の悪化はさらに深刻化した。 しかし、イランのドローン1機がフジャイラ港の石油ターミナルを攻撃し、施設内で大規模な火災が発生した。 日量1000万バレルという記録的な供給損失により、世界の石油在庫は既に枯渇しており、専門家は、ホルムズ海峡の封鎖が続く場合、このエネルギー危機は2026年末から2027年まで続く可能性があると警告している。
Related Articles
Avista Q1 Energy Volumes Drop Across Segments Amid Softer Demand
Avista (AVA) reported Q1 earnings Tuesday, with electricity and natural gas volumes declining as milder weather reduced demand, with residential usage down 10% and commercial down 6%.The company reported total residential electricity sales through its operating unit, Avista Utilities, at 1.15 gigawatt-hours, down from 1.27 GWh a year earlier.Electricity sales to the commercial sector were 768 megawatt-hours for the quarter ended March 31, compared with 808 MWh a year earlier.The company reported industrial electricity sales for 455 MWh for the quarter, down from 469 MWh a year earlier, while wholesale sales were 912 MWh, down from 951 MWh a year earlier.The company reported total residential natural gas sales through its operating unit, Avista Utilities, of 8,490.7 billion British thermal units delivered, down from 9,888.1 billion Btu delivered a year earlier.Commercial natural gas sales were 5,116.1 billion Btu delivered for the quarter ended March 31, compared with 5,961.9 billion Btu delivered a year earlier.The company reported wholesale natural gas volumes of 5,446.1 billion Btu delivered in Q1, down from 6,752.8 billion Btu delivered a year earlier.Other natural gas volumes were 5,446.1 billion Btu delivered for the quarter, compared with 5,401.9 billion Btu delivered a year earlier.Avista is also advancing a new enterprise resource planning system targeted for completion in 2028, with estimated capital expenditures of about $130 million to enhance operational efficiency and financial reporting capabilities.Price: $40.81, Change: $+0.25, Percent Change: +0.62%
Primo Brands' Q1 Faces Pressure From Service Disruptions, Cost Headwinds, RBC Says
Primo Brands (PRMB) is expected to face pressure in Q1 from extended service disruptions tied to winter storms and higher input costs linked to the Middle East conflict, RBC Capital Markets said in a note emailed Tuesday.The firm said Q1 is likely to be the weakest quarter of the year and could be further affected by lost or unrecoverable delivery sales from the winter storms.Retail business trends appear supportive, with sales growth of 6% in scanner data, RBC said, adding that the company has taken pricing on about 15% of its retail volume outside its core case pack business.Primo Brands also remains highly sensitive to petroleum-linked costs, including resin, glass, aluminum and diesel fuel, though it has significant hedge coverage in place for 2026 and levers such as pricing and fuel surcharges, the note said.Primo Brands is expected to report Q1 financial results on Thursday.RBC maintained its outperform rating on Primo Brands and kept its price target at $28.Price: $20.37, Change: $+0.27, Percent Change: +1.37%
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is entering a "transition year" in 2026, prioritizing growth acceleration and market share gains as its expanded enzyme portfolio scales following the acquisition of Amicus Therapeutics (FOLD), Morgan Stanley said in a report Tuesday.In its Q1 results, BioMarin raised its fiscal 2026 revenue guidance to $3.825 billion to $3.925 billion, driven by contributions from newly added therapies Galafold and Pombiliti plus Opfolda, but lowered its non-GAAP earnings per share outlook to $4.85 to $5.05 due to integration-related costs and higher interest expenses, associated with the transaction, the report said.BioMarin is focused on scaling its expanded enzyme portfolio and driving commercial execution, with its management expected to outline a detailed roadmap in Q2 covering "long-term revenue potential," peak sales and cost synergies, the investment bank said.Earnings are expected to be weighted toward the second half of 2026, with the Amicus deal seen by the management as "slightly dilutive" this year but "accretive" within 12 months and more meaningful in start of 2027, the report said.The "combined enzyme portfolio" is expected to support durable growth and help offset rising competition for Voxzogo, while pipeline developments and new launches, including Palynziq expansion and BMN-333, could further support long-term growth, according to the report.Morgan Stanley has an overweight rating on BioMarin Pharmaceutical and lowered its price target to $119 from $120.Price: $54.26, Change: $-1.20, Percent Change: -2.16%